HEAD-Study Optimizing the Treatment of Children With BECTS
Status:
Terminated
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The investigators hypothesize that Levetiracetam is as effective as Sulthiame in the
treatment of children with BECTS. Patients entering the HEAD-Studie are either treated with
Leveitracetam or Sulthiame over a 6 months period. Patients are equally randomised to one of
the two treatment regimens. Administration of medication as blinded capsules.